Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02101970 · ClinicalTrials.gov registry record · NA
Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women
A NA study, sponsored by Carol Fabian, MD.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT02101970: Completed NA study, sponsored by Carol Fabian, MD.
NCT02101970 is a NA study that has completed, run by Carol Fabian, MD. The registered enrollment target is 46 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02101970, a NA study, has completed, sponsored by Carol Fabian, MD.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if high dose supplementation with the omega-3 fatty acids EPA and DHA, when added to a weight loss program, is well tolerated in the study population and if there is an increase in the favorable change in blood and tissue breast cancer risk factors when compared to weight loss alone.
Primary Outcome
Measured as the number of participants that dropout before diet+intervention period is complete
Interventions
- OTHER Placebo Capsule
- DIETARY_SUPPLEMENT Omega-3 Fatty Acids
- OTHER Diet and Exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2014-03 |
| Est. Completion | 2018-08-27 |
| Phase | NA |
What the finished NCT02101970 record still lists
NCT02101970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo Capsule is the first listed.
NCT02101970 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02101970 about?
NCT02101970 is a clinical study titled "Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women". The purpose of this study is to determine if high dose supplementation with the omega-3 fatty acids EPA and DHA, when added to a weight loss program, is well tolerated in the study population and if there is an increase in the favorable change in blood and tissue breast cancer risk factors when comp...
What is the current status of trial NCT02101970?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2014-03. Estimated completion is 2018-08-27.
What interventions are being tested in trial NCT02101970?
The interventions under investigation include: Placebo Capsule (OTHER), Omega-3 Fatty Acids (DIETARY_SUPPLEMENT), Diet and Exercise (OTHER).
Who is sponsoring clinical trial NCT02101970?
This trial is sponsored by Carol Fabian, MD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02101970's enrollment target sits among peer trials
46 1402nd of 2000 higher than 590 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia